The treatment gap: The missed opportunities for osteoporosis therapy

Fracture Risk During and After Bisphosphonate Drug Holidays

(2020) Annette L. Adams   MEDICAL CARE

Zoledronate

(2020) Ian R. Reid et al.   BONE

History of alendronate

(2020) Steven R. Cummings et al.   BONE

Bisphosphonates and lifespan

(2020) Jacqueline R. Center et al.   BONE

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs

(2020) N. R. Fuggle et al.   DRUGS

Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton

(2020) Michael J. Rogers et al.   BONE

On the pharmacological evaluation of bisphosphonates in humans

(2020) Serge Cremers et al.   BONE

Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates

(2020) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fracture risk following intermission of osteoporosis therapy

(2019) E.M. Dennison et al.   OSTEOPOROSIS INTERNATIONAL

Deep neural networks for automatic detection of osteoporotic vertebral fractures on CT scans

(2018) Naofumi Tomita et al.   COMPUTERS IN BIOLOGY AND MEDICINE

Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study

(2018) Eugene McCloskey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study

(2018) David A Turner et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial

(2018) Lee Shepstone et al.   LANCET

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2018) J.A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Hip fracture risk and safety with alendronate treatment in the oldest-old

(2017) K. F. Axelsson et al.   JOURNAL OF INTERNAL MEDICINE

Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study

(2017) K. H. Rubin et al.   OSTEOPOROSIS INTERNATIONAL

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

(2017) N. C. W. Harvey et al.   OSTEOPOROSIS INTERNATIONAL

Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis

(2016) Samuel Hawley et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Secular trends in fracture incidence in the UK between 1990 and 2012

(2016) R. Y. van der Velde et al.   OSTEOPOROSIS INTERNATIONAL

Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery

(2016) S. Drew et al.   OSTEOPOROSIS INTERNATIONAL

Intravenous zoledronate for osteoporosis: less might be more

(2016) Andrew Grey   Therapeutic Advances in Musculoskeletal Disease

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2015) Dennis M. Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: A systematic review

(2015) Kareeann S. F. Khow et al.   Journal of Nutrition Health & Aging

Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool

(2015) M. K. Javaid et al.   OSTEOPOROSIS INTERNATIONAL

Using self-reports of pain and other variables to distinguish between older women with back pain due to vertebral fractures and those with back pain due to degenerative changes

(2015) E. M. Clark et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women

(2015) Susan L. Greenspan et al.   JAMA Internal Medicine

Clinician’s Guide to Prevention and Treatment of Osteoporosis

(2014) F. Cosman et al.   OSTEOPOROSIS INTERNATIONAL

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

(2013) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis

(2013) M. Tadrous et al.   OSTEOPOROSIS INTERNATIONAL

Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle

(2013) K. Åkesson et al.   OSTEOPOROSIS INTERNATIONAL

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies

(2013) P. D. Miller et al.   OSTEOPOROSIS INTERNATIONAL

Osteoporosis in the European Union: medical management, epidemiology and economic burden

(2013) E. Hernlund et al.   Archives of Osteoporosis

Best Practices in Secondary Fracture Prevention: Fracture Liaison Services

(2013) Paul J. Mitchell   Current Osteoporosis Reports

Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention

(2012) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Incidence of atypical nontraumatic diaphyseal fractures of the femur

(2012) Richard M Dell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study

(2012) L. Shepstone et al.   OSTEOPOROSIS INTERNATIONAL

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis

(2012) S. Lekamwasam et al.   Archives of Osteoporosis

The relationship between the chemistry and biological activity of the bisphosphonates

(2011) Frank H. Ebetino et al.   BONE

Bisphosphonates: The first 40years

(2011) R. Graham G. Russell   BONE

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis

(2011) René Rizzoli et al.   CALCIFIED TISSUE INTERNATIONAL

Atrial fibrillation and bisphosphonate therapy

(2011) Michael Pazianas et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: Cohort for skeletal health in Bristol and Avon (COSHIBA)

(2011) Emma M Clark et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Esophageal and gastric cancer incidence and mortality in alendronate users

(2011) Bo Abrahamsen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonate Use and Atypical Fractures of the Femoral Shaft

(2011) Jörg Schilcher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study

(2011) P. D. Miller et al.   OSTEOPOROSIS INTERNATIONAL

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

(2011) G. Bianchi et al.   OSTEOPOROSIS INTERNATIONAL

Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure

(2009) Joan C. Lo et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY